At a glance

ClinicalIndex Comparison Record

Phase 4Completed· 1,991 enrolled

Drug / intervention

liraglutide +6 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02730377

NCT02730377Phase 4Completed

Compare CT.gov

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting

Novo Nordisk A/S·interventional·Posted Apr 6, 2016·Updated Jul 7, 2020

In Brief

A Phase 4 clinical trial evaluating liraglutide, alpha-glucosidase inhibitors, and 5 other interventions for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 1,991 participants across 232 sites in 10 countries.

Detailed Summary

This trial is conducted globally. The aim of the trial is to investigate efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin background treatment vs. OADs as add-on to metformin background treatment for 104 weeks of treatment in subjects with type 2 diabetes.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsDiabetes, Diabetes Mellitus, Type 2

CountriesCanada, Colombia, India, Latvia, Lebanon, Puerto Rico, Russia, Serbia, Turkey (Türkiye), United States

Collaborators--

Timeline

Phase 4CompletedFinished

20162017201820192020202120222023202420252026

Enrollment StartMar 2016

First PostedApr 2016

Primary CompletionAug 2019

Study CompletionAug 2019

TodayJul 2026

First PostedApr 6, 2016

Enrollment StartMar 28, 2016

Primary CompletionAug 5, 2019

Study CompletionAug 12, 2019

TodayJul 2, 2026

Enrollment to primary: 3.4 yearsPosted 10.2 years ago